Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 13, Number 2—February 2007

Research

Neutralizing Antibodies after Infection with Dengue 1 Virus

Gustavo Kourí*Comments to Author , Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman*Comments to Author , and Scott B Halstead§
Author affiliations: *“Pedro Kourí” Tropical Medicine Institute, Havana, Cuba; †Instituto Medicina Tropical, Caracas, Venezuela; ‡Centre for Ecology and Hydrology, Oxford, United Kingdom; §Pediatric Dengue Vaccine Initiative, Bethesda, Maryland, USA;

Main Article

Figure

Log10 antibody (Ab) titers for human dengue virus type 1–immune serum samples collected in 1999 (89 samples) and 1981–1985 (50 samples, mean).

Figure. Log10 antibody (Ab) titers for human dengue virus type 1–immune serum samples collected in 1999 (89 samples) and 1981–1985 (50 samples, mean).

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO